Evaluating Modes of Influenza Transmission Observational Study of Community Acquired Influenza
NCT01769430 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 178
Last updated 2025-04-25
Summary
The recent swine origin influenza pandemic (2009), new emergence of swine origin H3N2v, and delayed availability of vaccine for these agents highlight the need to test and optimize public health intervention strategies to reduce transmission of influenza. We will use a new technology for biological particle collection (U.S. Provisional Patent Application No. 61/162,395, McDevitt et al., Aerosol Sci Technol 2013) to make fundamental observations on infectious respiratory droplets in a study of up to 200 naturally occurring seasonal influenza cases. We will collect respiratory droplets shed by participants while breathing normally, talking, and spontaneously coughing. We will characterize the size distribution of droplets containing infectious virus. We will use these basic data to examine the roles of large and small respiratory droplets and examine how the interaction of host factors and virus type impact the shedding of infectious respiratory droplets. Subjects will be recruited through a web based respiratory illness surveillance system, health clinics and advertisement in the campus community. Sitting in the collection booth will not create additional discomfort or risk for volunteers already suffering from influenza infection. We will recruit up to 1000 persons with symptoms of acute respiratory illness for screening with collection of nasopharyngeal swabs and questionnaire. From among those screened, we will recruit 250 to give exhaled breath samples, and ask 50 people with influenza to return for follow up exhaled breath samples on up to two subsequent days. We hypothesize that (1) fine aerosols (\<5 microns in aerodynamic diameter) will contain more viral copies than coarse aerosol particles (\>= 5 microns) (2) fine aerosols will contain culturable virus indicating that the fine aerosols are infectious, (3) aerosol shedding will correlate with virus load measured by swabs, (4) presence of active cough during sampling will be associated with increased aerosol shedding, (5) clinical symptoms and signs, including fever can be used to predict viral aerosol shedding.
Conditions
- Influenza Virus Infection Transmission in Humans
Interventions
- OTHER
-
Observational Study of influenza aerosol shedding -- No Intervention
No intervention -- observational study only
Sponsors & Collaborators
-
Centers for Disease Control and Prevention
collaborator FED -
National Institute of Allergy and Infectious Diseases (NIAID)
collaborator NIH -
University of Maryland, College Park
lead OTHER
Principal Investigators
-
Donald K Milton, MD, DrPH · University of Maryland
Eligibility
- Min Age
- 10 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2012-12-31
- Primary Completion
- 2013-03-31
- Completion
- 2013-03-31
Countries
- United States
Study Locations
More Related Trials
-
Respiratory Virus Hospitalization Study (FLU 003 Plus)
NCT01056185 ·Status: COMPLETED
-
Household Influenza Transmission Study
NCT01251679 ·Status: COMPLETED ·Phase: NA
-
Study to Assess the Burden of Mild Outcomes (Physician Office Visits) Due to Influenza in the United States
NCT02019732 ·Status: COMPLETED
-
A Randomised Controlled Trial of Face Masks and Hand Hygiene in Reducing Influenza Transmission in Households
NCT00425893 ·Status: COMPLETED ·Phase: NA
-
Virus Shedding and Environmental Deposition of a Novel Influenza Virus
NCT01046734 ·Status: COMPLETED
-
2009 H1N1 Pandemic and Seasonal Influenza in SCI/D: Infection Control Strategies
NCT01270685 ·Status: WITHDRAWN
-
Safety and Immunogenicity of Influenza H9 Vaccine in Humans
NCT00814229 ·Status: COMPLETED ·Phase: PHASE1
-
A Study of Exclusion Criteria in a University Population
NCT01472536 ·Status: COMPLETED ·Phase: NA
-
Study of Immune Responses in Healthy Adults Receiving Live Influenza Virus Vaccines
NCT01674205 ·Status: COMPLETED ·Phase: PHASE1
-
Dose, Safety, and Pathogenicity of a New Influenza H1N1 Challenge Strain
NCT05572450 ·Status: COMPLETED ·Phase: NA
-
A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.
NCT06178991 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity of Influenza Vaccinations
NCT06518577 ·Status: COMPLETED ·Phase: PHASE4
-
Biomarkers Predicting Infectivity in an Experimental Human Influenza Model
NCT03207152 ·Status: UNKNOWN ·Phase: PHASE1
-
Safety Study of an Influenza Vaccine Against a Potential Pandemic Strain of Flu
NCT00347529 ·Status: COMPLETED ·Phase: PHASE1
-
B-cell Immunity to Influenza (SLVP017)- Year 1, 2009
NCT02133781 ·Status: COMPLETED ·Phase: PHASE4
-
Safety, Tolerability, Efficacy and Immunogenicity of an Influenza A Vaccine (FP-01.1) in Healthy Volunteers Following Virus Challenge
NCT02071329 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Evaluation of Influenza-Specific Immune Responses in Children and Adults During the 2010-2011 Influenza Season in the U.S.
NCT01262079 ·Status: COMPLETED
-
A Safety and Immunogenicity Study of IVACFLU-A/H5N1
NCT02612909 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Immunogenicity Study of an Inactivated Influenza Vaccine (Split Virus, Vero Cell Derived) to Prevent Culture Confirmed Influenza Infection
NCT00800605 ·Status: COMPLETED ·Phase: PHASE3
-
Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza?
NCT01001325 ·Status: COMPLETED ·Phase: PHASE3
-
B-cell Immunity to Influenza (SLVP017) - Years 2 (2010) & 3 (2011)
NCT03020498 ·Status: COMPLETED ·Phase: PHASE4
-
Collaborative Efforts to Increase Flu Vaccination
NCT01403649 ·Status: COMPLETED ·Phase: NA
-
Intervention Study of Face Mask and Hand Sanitizer to Reduce Influenza Transmission
NCT00490633 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of Two Doses of H5N1 Influenza Vaccine in Elderly Subjects
NCT01766921 ·Status: COMPLETED ·Phase: PHASE2
-
Evaluating the Safety and Immune Response to an H5N1 Influenza Vaccine in People Who Have Previously Received an H5N1 or H7N3 Influenza Vaccine and in People Who Have Never Received a Live Attenuated Influenza Vaccine
NCT01443663 ·Status: COMPLETED ·Phase: PHASE1